Press Releases

 
Press Releases
Date Title and Summary View
Oct 15, 2012 SALT LAKE CITY, Oct. 15, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the first fiscal quarter 2013 following the close of market on Monday, November 5, 2012. The Company will also host a conference call on Monday, November 5, 2012 at 4:30 P.M. Eastern to review the fi...
Oct 10, 2012 SALT LAKE CITY, Oct. 10, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a study published in the British Journal of Cancer demonstrated the ability of the Company's Homologous Recombination Deficiency (HRD) Assay to detect loss of DNA repair in ovarian tumors. The study, entitled, "Patterns of Genomic Loss of Hete...
Oct 3, 2012 SALT LAKE CITY, Oct. 3, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that, in support of National Hereditary Breast and Ovarian Cancer (HBOC) Week and National Previvor Day, it has launched an online quiz to help people assess their risk for hereditary cancers. The Hereditary Cancer Quiz is available online at www.he...
Sep 24, 2012 SALT LAKE CITY, Sept. 24, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Noridian, the Medicare Administrator for Utah, has notified Myriad of its intent to add the Company's prostate prognostic test, Prolaris®, to its next draft Non-Covered Service LCD (local coverage determination). Noridian will solicit pu...
Aug 30, 2012 SALT LAKE CITY, Aug. 30, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present at the Morgan Stanley Global Healthcare Conference, at 1:00 p.m. Eastern Time on Wednesday, September 12, 2012. The conference is being held at The Grand Hyatt New York in New York, ...
Aug 16, 2012 SALT LAKE CITY, Aug. 16, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) reported today that the United States Court of Appeals for the Federal Circuit declared that the Company's composition of matter claims covering isolated DNA of the BRCA 1 and BRCA 2 genes are patent-eligible material under Section 101 of the United States Patent ...
Aug 14, 2012 SALT LAKE CITY, Aug. 14, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results for its fourth quarter and fiscal year ending June 30, 2012. Revenue for the fourth fiscal quarter increased 24 percent over the same period in the prior year to $133.0 million and resulted in fiscal year 2012 revenue of $496.0 million, an ...
Jul 26, 2012 SALT LAKE CITY, July 26, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has signed an agreement with Pharma Mar, a leader in the development of marine-derived drugs. Under the agreement, Myriad will conduct BRCA 1 and BRCA 2 testing on patients to be enrolled in a Phase II clinical study of PM1183, a novel drug...
Jul 24, 2012 SALT LAKE CITY, July 24, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the fourth fiscal quarter and fiscal year 2012 following the close of market on Tuesday, August 14, 2012. The Company will also host a conference call on Tuesday, August 14, 2012 at 4:30 P.M. Eastern...
Jun 6, 2012 SALT LAKE CITY, June 6, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics announced today that the Company is the honorable recipient of the 2012 Charles R. Smart Visionary Award from the American Cancer Society's Salt Lake City office, a part of the Great West Division. This award is presented annually at the Society's Legacy & Leadership event to recogniz...
Page: FirstPrevious ...
10
... NextLast
= add release to Briefcase